Heartseed, Inc. AI Stock Analysis
Want to see JP:219A full AI Analyst Report?
Heartseed, Inc. (219A) AI Stock Analysis
Heartseed, Inc.
(TSE/TYO:219A)
The score is driven primarily by the FY2025 financial turnaround (profitability and positive free cash flow) and a strong technical uptrend with positive momentum. These are tempered by valuation risk from a negative P/E and the company’s prior multi-year losses and cash burn, which raise durability and volatility concerns.
Heartseed, Inc. (219A) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 67.80B
- Dividend Yield
- ―
- Average Volume (3M)
- 510.38K
- Price to Earnings (P/E)
- -100.2
- Beta (1Y)
- 0.85
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Japan
- Employees
- 43
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Heartseed, Inc. Business Overview & Revenue Model
Company Description
Heartseed Inc. is a Japan-based company engaged in research and development of regenerative medicine products. The company has established cardiac regenerative medicine, a therapy in which microtissue derived from iPS cells is transplanted into the h...
Heartseed, Inc. Financial Statement Overview
Summary
FY2025 shows a strong inflection with sharp revenue growth, solid profitability (about 20% net margin; ~23% EBIT margin), and a shift to positive operating/free cash flow, supported by a very low-debt balance sheet. The key risk is volatility: FY2022–FY2024 had large losses and cash burn, and margin comparability is reduced by inconsistent gross profit reporting (FY2025 shows zero gross profit).
Income Statement
62PositiveBalance Sheet
86Very PositiveCash Flow
67Positive| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.03B | 3.03B | 873.61M | 344.73M | 499.06M |
| Gross Profit | 3.03B | 3.03B | 0 | 0 | 0 |
| EBITDA | 778.63M | 278.71M | -996.98M | -1.45B | -1.46B |
| Net Income | 592.50M | 163.38M | -812.73M | -1.47B | -1.41B |
Balance Sheet | |||||
| Total Assets | 8.14B | 8.14B | 7.07B | 5.72B | 4.94B |
| Cash, Cash Equivalents and Short-Term Investments | 7.34B | 7.34B | 5.30B | 4.59B | 3.99B |
| Total Debt | 890.00K | 890.00K | 5.39M | 11.58M | 30.98M |
| Total Liabilities | 571.35M | 571.35M | 444.34M | 450.19M | 208.45M |
| Stockholders Equity | 7.57B | 7.57B | 6.62B | 5.27B | 4.73B |
Cash Flow | |||||
| Free Cash Flow | 1.05B | 1.05B | -1.36B | -1.13B | -1.92B |
| Operating Cash Flow | 1.08B | 1.08B | -1.34B | -797.93M | -1.92B |
| Investing Cash Flow | 72.64M | 72.64M | -67.13M | -425.69M | -994.00K |
| Financing Cash Flow | 375.76M | 375.76M | 2.12B | 1.85B | -22.16M |
Heartseed, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:219A, the sentiment is Positive. The current price of 3025.00 is above the 20-day moving average (MA) of 2826.45, above the 50-day MA of 2632.78, and above the 200-day MA of 2007.93, indicating a bullish trend. The MACD of 106.10 indicates Positive momentum. The RSI at 60.07 is Neutral, neither overbought nor oversold. The STOCH value of 60.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:219A.
Heartseed, Inc. Peers Comparison
Overall Rating
- JP:219A71Outperform
JP:493171Outperform
JP:435060Neutral
JP:334959.9Neutral
JP:279643Neutral
JP:190A38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:219A | 71Outperform | JPY 69.48B | -100.20 | ― | ― | ― | ― |
| JP:4931 | 71Outperform | JPY 43.04B | 13.15 | ― | 2.86% | 3.38% | 32.41% |
| JP:4350 | 60Neutral | JPY 15.99B | 17.47 | ― | 2.31% | 6.89% | -55.21% |
| JP:3349 | 60Neutral | JPY 502.83B | 15.48 | ― | 1.31% | 8.99% | 3.61% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:2796 | 43Neutral | JPY 5.94B | 59.72 | ― | 2.77% | 7.64% | ― |
| JP:190A | 38Underperform | JPY 3.46B | -2.23 | ― | ― | ― | 24.21% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:219A | Heartseed, Inc. | 3025.00 | 1220.00 | 67.59% | |
| JP:2796 | Pharmarise Holdings Corp. | 506.00 | -16.92 | -3.24% | |
| JP:3349 | COSMOS Pharmaceutical Corporation | 6236.00 | -1078.62 | -14.75% | |
| JP:4350 | Medical System Network Co., Ltd. | 519.00 | 28.22 | 5.75% | |
| JP:4931 | Shinnihonseiyaku Co., Ltd. | 1991.00 | -65.96 | -3.21% | |
| JP:190A | Chordia Therapeutics Inc. | 45.00 | -62.00 | -57.94% |
Heartseed, Inc. Corporate Events
Heartseed’s HS-001 Receives Orphan Regenerative Medical Product Designation
Heartseed said its lead pipeline product, allogeneic iPS cell-derived cardiomyocyte spheroids HS-001, received orphan regenerative medical product designation from Japan’s Ministry of Health, Labour and Welfare on November 9, 2026. The designation co...
Heartseed’s HS-001 Designated SAKIGAKE Regenerative Medical Product
Heartseed Inc. is developing regenerative medical products, including HS-001, an allogeneic iPS cell-derived cardiomyocyte spheroid product for transplantation into the myocardium during CABG. Its stated target is severe heart failure secondary to is...
Heartseed Advances HS-005 Cardiac Cell Therapy With First Ischemic Heart Disease Patient Dosed
Heartseed Inc. has dosed the first patient with severe heart failure secondary to ischemic heart disease in its EMERALD Phase I/II clinical trial of HS-005, an allogeneic iPS cell-derived cardiomyocyte spheroid therapy delivered via catheter. An Inde...
Heartseed Director Resigns After Appointment as Japan’s Digital Minister
Heartseed Inc. announced the resignation of independent board director Toshiharu Furukawa, effective September 17, 2026, following his appointment as Minister of State and Minister for Digital Transformation. The company stated it will continue to me...
Heartseed Secures ¥2 Billion Credit Line to Advance Heart Failure Cell Therapy
Heartseed Inc. has secured a 2 billion yen special overdraft facility from Sumitomo Mitsui Banking Corporation to support its push toward manufacturing and marketing approval for its lead cardiomyocyte replacement therapy, HS-001. The unsecured, one-...
Heartseed Books Subsidy-Driven Non-Operating Gain Without Changing Outlook
Heartseed Inc. reported non-operating income of 69,833 thousand yen for the six months ended June 30, 2026, driven mainly by a 52,000 thousand yen subsidy tied to the Japan Agency for Medical Research and Development’s program for basic technology de...
Heartseed posts interim loss but keeps strong equity base as R&D weighs on 2026 outlook
Heartseed Inc. reported non-consolidated net sales of ¥467 million for the six months ended June 30, 2026, down from ¥1,919 million in the prior comparable period, and swung to an interim net loss of ¥554 million, versus a previous profit of ¥707 mil...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 19, 2026